{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:07:43Z","timestamp":1773770863855,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.reuma.2011.11.006","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T14:28:08Z","timestamp":1328624888000},"page":"58-62","source":"Crossref","is-referenced-by-count":11,"title":["\u00bfSon necesarias las dosis elevadas de prednisona para el tratamiento de la neumopat\u00eda intersticial en la esclerosis sist\u00e9mica?"],"prefix":"10.1016","volume":"8","author":[{"given":"Dionisio","family":"P\u00e9rez Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Est\u00e9vez Del Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisa","family":"Pe\u00f1a Casanovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Pablo","family":"Gonz\u00e1lez Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisvenia","family":"Morales S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela Rosa","family":"Guti\u00e9rrez Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2011.11.006_bib0005","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2011.11.006_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.rhu.0000152147.38706.db","article-title":"The lung in systemic sclerosis","volume":"11","author":"Steen","year":"2005","journal-title":"J Clinical Rheumatol"},{"key":"10.1016\/j.reuma.2011.11.006_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.amjmed.2004.04.031","article-title":"Mortality in systemic sclerosis: an international meta-analysis of individual patient data","volume":"118","author":"Ioannidis","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.reuma.2011.11.006_bib0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0889-857X(05)70303-3","article-title":"Scleroderma clinical problems the lungs","volume":"22","author":"Silver","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.reuma.2011.11.006_bib0025","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"White","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reuma.2011.11.006_bib0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0889-857X(03)00025-5","article-title":"Interstitial lung disease in scleroderma","volume":"29","author":"White","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.reuma.2011.11.006_bib0035","first-page":"838","article-title":"Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease","volume":"20","author":"Silver","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2011.11.006_bib0040","first-page":"298","article-title":"Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease","volume":"29","author":"Pakas","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2011.11.006_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1756-185X.2009.01417.x","article-title":"High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study","volume":"12","author":"Wanchu","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reuma.2011.11.006_bib0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2011.11.006_bib0055","first-page":"198","article-title":"Prognosis and treatment of interstitial lung disease in systemic sclerosis: an update Bull NYU","volume":"66","author":"Varga","year":"2008","journal-title":"Hosp Jt Dis"},{"key":"10.1016\/j.reuma.2011.11.006_bib0060","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2011.11.006_bib0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/rheumatology\/31.7.457","article-title":"Reliability of skin involvement measures in scleroderma","volume":"31","author":"Brennan","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.reuma.2011.11.006_bib0070","doi-asserted-by":"crossref","unstructured":"Guidelines for the measurement of respiratory function: recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Resp Med. 1994;88:165\u201394.","DOI":"10.1016\/S0954-6111(05)80346-4"},{"key":"10.1016\/j.reuma.2011.11.006_bib0075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1148\/radiol.2322031223","article-title":"CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia","volume":"232","author":"Desai","year":"2004","journal-title":"Radiology"},{"key":"10.1016\/j.reuma.2011.11.006_bib0080","first-page":"1520","article-title":"High resolution computed tomography in early scleroderma lung disease","volume":"18","author":"Warrick","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2011.11.006_bib0085","first-page":"46","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment international consensus statement","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.reuma.2011.11.006_bib0090","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1136\/ard.2007.069518","article-title":"Scleroderma lung study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis","volume":"66","author":"Clements","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2011.11.006_bib0095","first-page":"592","article-title":"Among a group of patients with dyspnea and alveolitis entering the scleroderma lung study (SLS), a surprising proportion have limited SSc (LSSc)","volume":"52","author":"Furst","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2011.11.006_bib0100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/keg170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Hesselstrand","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2011.11.006_bib0105","first-page":"51","article-title":"Clinical and sociodemographic features of puerto ricans with systemic sclerosis","volume":"20","author":"Rios","year":"2010","journal-title":"Ethn Dis"},{"key":"10.1016\/j.reuma.2011.11.006_bib0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11926-009-0016-2","article-title":"Current concepts in disease-modifying therapy for systemic sclerosis\u2013associated interstitial lung disease: lessons from clinical trials","volume":"11","author":"Karen Au","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.reuma.2011.11.006_bib0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/01.rti.0000213572.16904.40","article-title":"Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis","volume":"22","author":"Shah","year":"2007","journal-title":"J Thorac Imaging"},{"key":"10.1016\/j.reuma.2011.11.006_bib0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1055\/s-2007-985613","article-title":"The spectrum of scleroderma lung disease","volume":"28","author":"Highland","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.reuma.2011.11.006_bib0125","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2011.11.006_bib0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874306400802010039","article-title":"Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study","volume":"2","author":"Sime\u00f3n-Aznar","year":"2008","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.reuma.2011.11.006_bib0135","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2011.11.006_bib0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1164\/rccm.200705-655OC","article-title":"Scleroderma lung study research group bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease","volume":"177","author":"Strange","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.reuma.2011.11.006_bib0145","first-page":"265","article-title":"Cyclophosphamide: effective in the treatment of severe cutaneous involvement in systemic sclerosis","volume":"49","author":"Andrade de Macedo","year":"2009","journal-title":"Bras J Rheumatol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X11003755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X11003755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T12:52:07Z","timestamp":1543236727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X11003755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1699258X11003755"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2011.11.006","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}